ROE của cổ phiếu BHVN là bao nhiêu?

BIOHAVEN LTD. có tỷ suất lợi nhuận trên vốn chủ sở hữu (ROE) -500.14%.

Tỷ suất cổ tức của BHVN là bao nhiêu?

BIOHAVEN LTD. có tỷ suất cổ tức 0.00%.

Điểm chất lượng (Quality Score) của BHVN là bao nhiêu?

AI của chúng tôi đánh giá chất lượng tài chính tổng thể của BHVN ở mức 46/100, dựa trên khả năng sinh lời, tăng trưởng, nợ và độ ổn định lợi nhuận.

Bây giờ có nên mua cổ phiếu BHVN không?

Điểm AI Timing của BHVN là 70/100, thể hiện mức độ hấp dẫn tương đối của giá hiện tại theo tín hiệu kỹ thuật và momentum — nên cân nhắc cùng điểm chất lượng và kế hoạch đầu tư của bạn.

Cổ phiếu BHVN thuộc ngành nào?

BIOHAVEN LTD. được xếp vào ngành Healthcare >> Biotechnology trên sàn NYSE

Cổ phiếu BHVN (NYSE) | BIOHAVEN LTD.

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

BHVN AI Analysis Summary

Our AI summary for BHVN: BIOHAVEN LTD. (NYSE), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -500.14%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 70/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

BHVN

BIOHAVEN LTD.

US:NYSE STOCK Healthcare >> Biotechnology News 85

USD 13.50

-0.32 (-2.32%) Day Change

Watchlist Portfolio Compare Chart

1.91

D/E

-500.1%

ROE

-138.9%

ROA

0.00%

Div Yield

BIOHAVEN LTD.
TYPE: STOCK
MARKET: NYSE

Compare Watchlist Myport

USD 13.50 Price -0.32 (-2.32%) Day Change	NEWS SCORE: 85

BHVN Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 46) nhưng Thời điểm mua ...(Sign In to See)...

Loading chart...

46 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
Lịch sử ROE tương đối thấp
Tăng trưởng ROE là âm trong năm ngoái.
Tăng trưởng ROA dưới mức tiêu chí của chúng tôi trong năm vừa qua
Biên lợi nhuận ròng tương đối thấp.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Không tốt , ...

Yếu tố Chất lượng

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	85
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	13.50
PBV / Sector	16.07 / 5.20
Earning Per Share	-4.20

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	27.92 M GREAT
Average 1W Daily Value	23.87 M GREAT

Yếu tố Kỹ thuật

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Sức khỏe tài chính

39%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Khả năng kiếm lợi nhuận

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.71
NPM Average (%) / Sector	N/A / -1,721.76
NPM Change Average (%) / Sector	N/A / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-138.87 / 27.02
ROA Average (%) / Sector	-121.17 / -368.17
ROA Change Average (%) / Sector	17.27 / 5,404.12 GOOD
ROE (%) / Sector	-500.14 / 3.47
ROE Average (%) / Sector	-464.02 / 6.51
ROE Change Average (%) / Sector	161.19 / 2,128.13 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Lợi tức cho nhà đầu tư

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Chi tiết đăng ký

Analyze Date	2026-08-01 07:59:33
Symbol	BHVN
Name	BIOHAVEN LTD.
Sector	Healthcare >> Biotechnology
Market	NYSE
Listed Shares	150.56 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	2,080.75 / 9,903.94

Tin tức, Dự báo ước tính

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 215 Church Street, New Haven, CT, United States, 06510

Phone: 203 404 0410

Website: https://www.biohaven.com

Employees: 274

Sector: Healthcare >> Biotechnology

Description: Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.